EP1268856A2 - Detection de polymorphismes du nucleotide simple et de methylation de cytosine - Google Patents

Detection de polymorphismes du nucleotide simple et de methylation de cytosine

Info

Publication number
EP1268856A2
EP1268856A2 EP01923891A EP01923891A EP1268856A2 EP 1268856 A2 EP1268856 A2 EP 1268856A2 EP 01923891 A EP01923891 A EP 01923891A EP 01923891 A EP01923891 A EP 01923891A EP 1268856 A2 EP1268856 A2 EP 1268856A2
Authority
EP
European Patent Office
Prior art keywords
single nucleotide
nucleotide polymorphisms
oligonucleotides
genomic dna
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01923891A
Other languages
German (de)
English (en)
Inventor
Alexander Olek
Christian Piepenbrock
Kurt Berlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epigenomics AG
Original Assignee
Epigenomics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenomics AG filed Critical Epigenomics AG
Publication of EP1268856A2 publication Critical patent/EP1268856A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present invention describes a representative set of oligonucleotides or PNA (peptide nucleic acid) oligomers which are particularly suitable for simultaneously detecting SNPs (single nucleotide polymorphisms) and cytosine methylations in genomic DNA samples to distinguish cell types. and a method used.
  • SNPs single nucleotide polymorphisms
  • cytosine methylations in genomic DNA samples to distinguish cell types.
  • the human genome project the first sequencing of the human genome, will be completed in the next few years. This project will make it possible to identify all of the approximately 100,000 genes. Sequence information opens up undreamt-of possibilities for elucidating gene functions. This in turn opens up the possibility of doing pharmacogenetics and pharmacogenomics.
  • Pharmacogenetics and pharmacogenomics target the use of drugs depending on a genotype. The aim is to increase the effectiveness of medication.
  • the necessary intermediate step is the determination of the position lymorphisms and genotypes associated with a particular response. Therefore, increasingly efficient genotyping methods are required.
  • Microsatellites are highly polymorphic, i.e. they have a variety of alleles. They are characterized in that a repetitive sequence element with a different number of repetitions for different alleles is franked by conserved sequences. There is an average of one microsatellite marker per million bases. A map of 5,000 positioned microsatellite markers has been published by CEPH. Microsatellites are genotyped by determining the size of a PCR product with primers of the conserved, flanking sequence. The fluorescence-labeled PCR products are separated on gels.
  • SNP markers There are comparatively few described SNP markers. A card with 300,000 SNP markers is currently being developed by the SNP consortium and will be publicly available. Once the SNP markers have been identified, they can be assigned to genomic positions. The goal is to map 150,000 SNP markers by 2001 (Mashall, E. (1999); Science, 284, 406-407). There are a handful of genotyping methods for SNPS. Some are based on the separation of products on gels, such as the oligonucleotide ligase assay (OLA). It is therefore more suitable for medium throughput. Others rely on pure hybridization, which, however, does not have the same stringency. DNA arrays (DNA chips) are suitable for the analysis of a large number of SNPs in a limited number of individuals.
  • OVA oligonucleotide ligase assay
  • MALDI Matrix-assisted laser desorption / ionization time-of-flight mass spectrometry
  • MALDI has revolutionized the analysis of biomolecules (Karas, M. & Hillenkamp, F. Anal. Che. 60, 2299-2301 (1988)).
  • MALDI has been used in various variants for the analysis of DNA. The variants range from primer extension to sequencing (Liu, Y.-H., et al. Rapid Comraun. Mass Spectrom. 9, 735-743 (1,995); Ch'ang, L.-Y., et al. Rapid Commun. Mass Spectrom. 9, 772-774 (1995); Little, DP, et al. J. Mol. Med.
  • 5-methylcytosine The most frequently covalently modified base in the DNA of eukaryotic cells is 5-methylcytosine. For example, it plays a role in the regulation of transcription, in genetic imprinting and in tumorigenesis. The identification of 5-methylcytosine as a component of genetic information is therefore of considerable interest. However, 5-methylcytosine positions cannot be identified by sequencing since 5-methylcytosine has the same base pairing behavior as cytosine. In addition, in the case of PCR amplification, the epigenetic information which the 5-methylcytosines carry is completely lost.
  • the state of the art in terms of sensitivity is defined by a method which includes the DNA to be examined in an agarose matrix, thereby preventing the diffusion and renaturation of the DNA (bisulfite only reacts on single-stranded DNA) and all precipitation and purification steps replaced by rapid dialysis (Olek, A. et al., Nucl. Acids. Res. 1996, 24, 5064-5066).
  • This method individual cells can be examined, which illustrates the potential of the method.
  • only individual regions up to approximately 3000 base pairs in length have so far been investigated; global examination of cells for thousands of possible methylation analyzes is not possible.
  • this method too, cannot reliably analyze very small fragments from small sample quantities. Despite the diffusion protection, these are lost through the matrix.
  • Fluorescent-labeled probes have been used in many cases for scanning an immobilized DNA array.
  • the simple attachment of Cy3 and Cy5 dyes to the 5 'OH of the respective probe is particularly suitable for fluorescent labels.
  • the fluorescence of the hybridized probes is detected, for example, using a confocal microscope.
  • the dyes Cy3 and Cy5, among many others, are commercially available. task
  • the present invention is intended to provide a set of oligonucleotides or PNA oligomers and a method which are particularly suitable for the simultaneous detection of SNPs (single nucleotide polymorphisms) and cytosine methylations in genomic DNA samples.
  • SNPs single nucleotide polymorphisms
  • cytosine methylations in genomic DNA samples.
  • the task is therefore solved by a set of oligonucleotides or PNA (peptide nucleic acid) oligomers for the detection of single nucleotide polymorphisms (SNPs, single nucleotide polymorphisms) and for the detection of the cytosine methylation state in chemically pretreated genomic DNA, the base sequences being selected are from SEQ-ID: 1 to SEQ-ID: 382046.
  • SNPs single nucleotide polymorphisms
  • the set according to the invention includes both the base sequences with the SEQ-ID: 1 to SEQ-ID: 382046 itself and / or those by extending, shortening or changing the sequences mentioned with the SEQ-ID: 1 to SEQ-ID : 382046 contains.
  • the sentence according to the invention can thus be composed according to the invention from unchanged sequences and / or sequences modified in the manner according to the invention.
  • the present invention describes a set of oligomer probes (oligonucleotides and / or PNA oligomers) for the detection of single nucleotide polymorphisms and / or the cytosine methylation state in chemically pretreated genomic DNA, which is particularly preferably at least 10 of the listed oligonucleotide or PNA
  • the set of oligomer probes for the detection of single nucleotide polymorphisms and / or the cytosine methylation state in chemically pretreated genomic DNA comprises at least 100
  • Oligonucleotide or PNA sequences selected from the sequences SEQ-ID: 1 to SEQ-ID: 382046, or at least 100 PNA oligomers or oligonucleotide sequences, which in turn comprise the sequences listed there, namely the sequences SEQ-ID: 1 to SEQ ID: 382046.
  • the set of oligonucleotides for the detection of single nucleotide polymorphisms and the cytosine methylation state in the chemically pretreated genomic DNA is particularly preferably characterized in that the majority of the base sequences at the 5 'end and / or at the 3' end are each extended by a further base, the bases can be A, T or C.
  • the set of oligonucleotides for the detection of single nucleotide polymorphisms and the cytosine methylation state in the chemically pretreated genomic DNA is particularly preferably once again characterized in that the base sequences at the 5 'end and / or at the 3' end are in each case extended by a further base , where the bases can be A, T or G.
  • the set of oligonucleotides for the detection of single nucleotide polymorphisms and the cytosine methylation state in the chemically pretreated genomic DNA is preferably characterized in that the base sequence sequences at the 5 'end and / or at the 3' end are in each case extended by at least two further bases, where the bases can be A, T or C.
  • the set of oligonucleotides for the detection of individual nucleotide polymorphisms and the cytosine methylation state in the chemically pretreated genomic DNA is preferably characterized in that the majority of the base sequences at the 5 'end and / or at the 3' end are each extended by at least two further bases are present, wherein the bases can be A, T or G.
  • the set of PNA (peptide nucleic acid) oligomers for the detection of single nucleotide polymorphisms and the cytosine methylation state in the chemically pretreated genomic DNA is particularly preferably characterized in that at the 5 'end and / or at the 3' end of the oligomer a nucleobase is omitted.
  • Detection of individual nucleotide polymorphisms and the cytosine methylation state in the chemically pretreated genomic DNA is preferably characterized in that at least two nucleobases are omitted at the 5 'end and / or at the 3' end of the oligomer.
  • a representative set of oligonucleotides and / or PNA oligomers comprising oligomers and / or oligonucleotides according to the sequences SEQ-ID: 1 to SEQ-ID: 382046, is intended for the detection of cytosine methylations and single nucleotide polymorphisms in genomic DNA to differentiate between Cell types or tissues or used to study cell differentiation.
  • the following procedural steps are carried out one after the other:
  • a genomic DNA sample is chemically treated in such a way that at the 5 'position, unmethylated cytosine bases in uracil, Thy or another base which is similar to the cytosine in terms of hybridization behavior are converted.
  • the genomic DNA to be analyzed is preferably obtained from conventional sources for DNA, such as. B. cell lines, blood, sputum, stool, urine, brain spinal fluid, paraffin-embedded tissue, histological slides and all possible combinations thereof.
  • the amplification is carried out by means of the polymerase chain reaction (PCR), a thermostable DNA polymerase being used.
  • PCR polymerase chain reaction
  • a second process step more than ten different fragments are amplified from the chemically pretreated genomic DNA, each of which is less than 2000 base pairs long, using synthetic oligonucleotides as primers.
  • the oligonucleotides or PNA oligomers are bound to a solid phase at defined locations.
  • oligonucleotides and / or PNA- Oligomer sequences arranged on a flat solid phase in the form of a rectangular or hexagonal grid.
  • the solid phase surface preferably consists of silicon, glass, polystyrene, aluminum, steel, iron, copper, nickel, silver or gold.
  • the amplicates are hybridized to a set of oligonucleotides or PNA oligomers which comprise at least 10 of the above-mentioned sequences, namely the sequences SEQ-ID: 1 to SEQ-ID: 382046.
  • the amplification of several DNA sections is carried out in one reaction vessel.
  • the base sequences of the set of oligonucleotides according to the invention are mostly at the 5 'end and / or at the 3' end in each case by a further one Base extends forward, whereby the bases can be either A, T or G.
  • the base sequences of the set of oligonucleotides according to the invention are mostly at the 5 'end and / or at the 3' end each extended by at least two further bases, where the bases can be either A, T or C.
  • the base sequences of the set of oligonucleotides according to the invention for the detection of individual nucleotide polymorphisms and of the cytosine methylation state are mostly at the 5 'end and / or at the 3' end in each case by at least two further bases extended, whereby the bases can be either A, T or G.
  • a set of PNA oligomers from the above-mentioned base sequences is used, a nucleobase being omitted at the 5 'end and / or at the 3' end of the oligomer.
  • a set of PNA oligomers from the above-mentioned base sequences is used, at least two nucleobases being omitted at the 5 'end and / or at the 3' end of the oligomer.
  • At least 10 of the above-mentioned oligonucleotide or PNA sequences are used to detect the cytosine methylation state, or at least 10 PNA oligomers or oligonucleotide sequences which in turn comprise the sequences mentioned above, namely the sequences SEQ-ID: 1 to SEQ-ID: 382046.
  • At least 100 of the above-mentioned oligonucleotide or PNA sequences are used to detect the cytosine methylation state, or at least 100 PNA oligomer or oligonucleotide sequences which in turn comprise the sequences mentioned above, namely the sequences SEQ-ID: 1 to SEQ-ID: 382046.
  • At least one primer is bound to a solid phase.
  • different amplificates are arranged on the solid phase in the form of a rectangular or hexagonal grid.
  • the solid phase surface preferably consists of silicon, glass, polystyrene aluminum, steel, iron, copper, nickel, silver or gold.
  • the hybridized amplificates are detected.
  • the labels attached to the amplificates can be identified at any position on the solid phase at which an oligonucleotide sequence is located.
  • the labels of the amplified products are fluorescent labels.
  • the labels of the amplificates are radionuclides.
  • the amplificates carry removable mass markings which are detected in a mass spectrometer.
  • the amplified products, fragments of the amplified products or probes complementary to the amplified products are detected in the mass spectrometer.
  • the fragments generated have a single positive or negative net charge in the mass spectrometer for better detectability.
  • the set of oligonucleotides and / or PNA oligomers according to the invention is preferably used for diagnosis and / or Predict adverse events for patients or individuals.
  • the set of oligonucleotides and / or PNA oligomers according to the invention is preferably used for the diagnosis and / or prognosis of adverse events for patients or individuals, these adverse events belonging to at least one of the following categories: adverse drug effects; Cancers; CNS malfunction, damage or illness; aggressive symptoms or behavioral disorders; clinical, psychological and social consequences of brain injuries; psychotic disorders and personality disorders; Dementia and / or associated syndromes; cardiovascular disease, malfunction and damage; Malfunction, damage or disease of the gastrointestinal tract; Malfunction, damage or disease of the respiratory system; Injury, inflammation, infection, immunity and / or convalescence; Malfunction, damage or illness of the body as a deviation in the development process; Malfunction, damage or disease of the skin, muscles, connective tissue or bones; endocrine and metabolic dysfunction, injury or illness; Headache or sexual malfunction.
  • the set of oligonucleotides and / or PNA oligomers according to the invention is preferably used to differentiate between cell types or tissues or to investigate cell differentiation.
  • the invention furthermore relates to a kit which contains at least 10 oligonucleotides or PNA oligomers and primers for the preparation of the amplificates and instructions for carrying out the method.
  • Preferred according to the invention is a set of oligonucleotides for the detection of single nucleotide polymorphisms (SNPs, single nucleotide polymorphisms) and the cytosine methylation state in chemically pretreated genomic DNA, where the base sequences are mostly at the 5 'end and / or at the 3' end another base is extended, the bases can be either A, T or C.
  • a set of oligonucleotides is preferred for the detection of single nucleotide polymorphisms (SNPs, single nucleotide polymorphisms) and the cytosine methylation state in chemically pretreated genomic DNA, where the base sequences are mostly one more at the 5 'end and / or at the 3' end
  • the base is extended, and the bases can be either A, T or G.
  • a set of oligonucleotides for the detection of single nucleotide polymorphisms is preferred according to the invention
  • SNPs single nucleotide polymorphisms
  • cytosine methylation state in chemically pretreated genomic DNA, where the majority of the base sequences at the 5 'end and / or at the 3' end are each extended by at least two additional bases, the bases being either A, Can be T or C.
  • Preferred according to the invention is a set of oligonucleotides for the detection of single nucleotide polymorphisms (SNPs, single nucleotide polymorphisms) and the cytosine methylation state in chemically pretreated genomic DNA, where the base sequences are mostly at the 5 'end and / or at the 3' end in each case by at least two further bases are present in an extended manner, whereby the bases can be either A, T or G.
  • SNPs single nucleotide polymorphisms
  • cytosine methylation state in chemically pretreated genomic DNA
  • Oligomers for the detection of single nucleotide polymorphisms (SNPs, single nucleotide polymorphisms) and the cytosine methylation state in chemically pretreated genomic DNA, where a nucleobase is omitted at the 5 'end and / or at the 3' end of the oligomer.
  • SNPs single nucleotide polymorphisms
  • cytosine methylation state in chemically pretreated genomic DNA, where a nucleobase is omitted at the 5 'end and / or at the 3' end of the oligomer.
  • Preferred according to the invention is a set of PNA (peptide nucleic acid) oligomers for the detection of single nucleotide polymorphisms (SNPs, single nucleotide polymorphisms) and the cytosine methylation state in chemically pretreated genomic DNA, where in each case at the 5 'and / or at the 3' end of the Oligomers at least two nucleobases are omitted.
  • SNPs single nucleotide polymorphisms
  • a set of oligomer probes for detecting the cytosine methylation state and / or single nucleotide polymorphisms in chemically pretreated genomic DNA, comprising at least 10 of the above-mentioned oligonucleotide or PNA sequences, is preferred.
  • Preferred according to the invention is a set of oligomer probes (oligonucleotides and / or PNA oligomers) for the detection of the cytosine methylation state and / or of single nucleotide polymorphisms in chemically pretreated genomic DNA, comprising at least 100 of the above-mentioned oligonucleotide or PNA sequences.
  • the present invention also relates to a method for analyzing a representative set of cytosine methylations and single nucleotide polymorphisms in genomic DNA samples to distinguish cell types.
  • a method for analyzing a representative set of cytosine methylations and single nucleotide polymorphisms in genomic DNA samples to distinguish cell types.
  • chemical treatment at the 5-position unmethylated cytosine bases is converted into uracil, thymidine or another base which is not similar to cytosine in terms of hybridization behavior.
  • the amplificates are hybridized to a set of oligonucleotides or PNA oligomers, comprising at least 10 of the above
  • the non-hybridized amplificates are removed.
  • the hybridized amplificates are detected.
  • the chemical treatment is carried out by means of a solution of a bisulfite, bisulfite or disulfite.
  • the amplification is carried out by means of the polymerase chain reaction (PCR). It is preferred according to the invention that the oligonucleotides or PNA oligomers are bound to a solid phase at defined locations.
  • PCR polymerase chain reaction
  • oligonucleotides and / or PNA oligomer sequences are arranged on a flat solid phase in the form of a rectangular or hexagonal grid.
  • markings attached to the amplifiers can be identified at any position of the solid phase at which an oligonucleotide sequence is located.
  • At least one primer is bound to a solid phase during the amplification.
  • different amplificates are arranged on the solid phase in the form of a rectangular or hexagonal grid.
  • the labels of the amplified products are fluorescent labels.
  • the labels of the amplificates are radionuclides.
  • the amplificates carry removable mass markings which are detected in a mass spectrometer.
  • the amplificates, fragments of the amplificates or probes complementary to the amplificates are detected in the mass spectrometer. It is preferred according to the invention that the fragments generated have a single positive or negative net charge for better detectability in the mass spectrometer.
  • the detection is carried out and visualized using matrix-assisted laser desorption / ionization mass spectrometry (MALDI) or using electrospray mass spectrometry (ESI).
  • MALDI matrix-assisted laser desorption / ionization mass spectrometry
  • ESI electrospray mass spectrometry
  • the polymerases are heat-resistant DNA polymerases.
  • the amplification of several DNA sections is carried out in one reaction vessel.
  • the solid phase surface consists of silicon, glass, polystyrene, aluminum, steel, iron, copper, nickel, silver or gold.
  • the genomic DNA was obtained from a DNA sample, sources of DNA e.g. B. cell lines, blood, sputu, stool, urine, brain spinal fluid, paraffin-embedded tissue, histological slides and all possible combinations thereof.
  • sources of DNA e.g. B. cell lines, blood, sputu, stool, urine, brain spinal fluid, paraffin-embedded tissue, histological slides and all possible combinations thereof.
  • the invention also relates to the use of a set of at least 10 of the above-mentioned oligonucleotides and / or PNA oligomers, selected from the sequences SEQ-ID: 1 to SEQ-ID: 382046, or of at least 10 oligomers or oligonucleotides which comprise the above sequences include, for the diagnosis and / or prognosis of adverse events for patients or individuals.
  • oligonucleotides and / or PNA oligomers selected from the sequences SEQ ID: 1 to SEQ ID: 382046, or else at least 10 oligomers or oligonucleotides which comprise the above sequences include, for the diagnosis and / or prognosis of adverse events for patients or individuals, these adverse events belonging to at least one of the following categories: adverse drug effects, cancer; CNS malfunction, damage or illness; aggressive symptoms or behavioral disorders; clinical, psychological and social consequences of brain injuries, psychotic disorders and personality disorders; Dementia and / or associated syndromes; cardiovascular disease, malfunction and
  • a set of at least 10 of the above-mentioned oligonucleotides and / or PNA oligomers selected from the sequences SEQ-ID: 1 to SEQ-ID: 382046, or of at least 10 oligomers or oligonucleotides which meet the above mentioned sequences include, to differentiate between cell types or tissues or to study cell differentiation.
  • the present invention also relates to a kit containing at least 10 of the above-mentioned oligonucleotides and / or PNA oligomers, selected from the sequences SEQ-ID: 1 to SEQ-ID: 382046, or of at least 10 oligomers or oligonucleotides which comprise the above sequences include, and primers for the preparation of the amplificates and instructions for performing the method according to the invention.
  • sequence listing with the sequences SEQ-ID: 1 to SEQ-ID: 382046 is enclosed with the international application in electronically readable form and is part of this application.

Abstract

L'invention concerne un ensemble d'oligonucléotides ou d'oligomères PNA et un procédé qui convient à la détection de méthylation de cytosine et du polymorphisme du nucléotide simple (SNP) dans des prélèvements d'ADN génomiques. Ce procédé sert au diagnostic et/ou au pronostic d'événements préjudiciables chez des patients ou des individus, tels que des maladies.
EP01923891A 2000-04-07 2001-04-06 Detection de polymorphismes du nucleotide simple et de methylation de cytosine Withdrawn EP1268856A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10019173 2000-04-07
DE10019173 2000-04-07
PCT/IB2001/000713 WO2001077384A2 (fr) 2000-04-07 2001-04-06 Detection de polymorphismes du nucleotide simple et de methylation de cytosine

Publications (1)

Publication Number Publication Date
EP1268856A2 true EP1268856A2 (fr) 2003-01-02

Family

ID=7639166

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01923891A Withdrawn EP1268856A2 (fr) 2000-04-07 2001-04-06 Detection de polymorphismes du nucleotide simple et de methylation de cytosine

Country Status (4)

Country Link
US (1) US20040241651A1 (fr)
EP (1) EP1268856A2 (fr)
AU (1) AU2001250572A1 (fr)
WO (1) WO2001077384A2 (fr)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262249B1 (en) * 1998-06-23 2001-07-17 Chiron Corporation Pancreatic cancer genes
DE10048091A1 (de) * 2000-09-28 2002-04-25 Ernst Bayer Anwendung chemisch modifizierter Oligodesoxyribonukleotide zur Unterdrückung der Proliferation von humanem Pankreastumor
US7612194B2 (en) * 2001-07-24 2009-11-03 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US7888324B2 (en) * 2001-08-01 2011-02-15 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7176303B2 (en) * 2003-11-06 2007-02-13 Isis Pharmaceuticals, Inc. Modulation of STAT5 expression
AU2003235584A1 (en) * 2002-01-18 2003-07-30 Genomar Asa Verification of fish origin based on nucleic acid pattern recognition
WO2003064701A2 (fr) * 2002-01-30 2003-08-07 Epigenomics Ag Procede d'analyse de motifs de methylation de cytosine
JP2003289869A (ja) * 2002-04-02 2003-10-14 Tosoh Corp 非定型抗酸菌Ｍｙｃｏｂａｃｔｅｒｉｕｍａｖｉｕｍ検出のためのオリゴヌクレオチドおよび検出法
AU2003228165B2 (en) * 2002-05-06 2008-05-08 Genesis Research And Development Corporation Limited Compositions isolated from forage grasses and methods for their use
DE60229920D1 (de) * 2002-05-21 2009-01-02 Mtm Lab Ag Marker für Lungentumore
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US20070054266A1 (en) * 2002-05-28 2007-03-08 National Institute Of Advanced Industrial Science And Technology Chemical sensor system
JP2004016054A (ja) * 2002-06-13 2004-01-22 Takara Bio Inc ポリペプチドの細胞表面局在化方法
WO2004006941A1 (fr) * 2002-07-17 2004-01-22 Index Pharmaceuticals Ab Composes antisens, methodes et compositions pour le traitement de troubles inflammatoires
EP1403384A1 (fr) * 2002-09-26 2004-03-31 Stichting Researchfonds Pathologie Procédé pour la détection et l'identification des HPV cutanés et amorces et sondes pour ce procédé
WO2004029577A2 (fr) * 2002-09-26 2004-04-08 Fmc Corporation Kinase a chaine legere de la myosine des hemipteres
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
CA2512110A1 (fr) 2002-12-31 2004-07-22 Mmi Genomics, Inc. Compositions, procedes et systemes d'inference concernant la race bovine
DK2267136T3 (da) * 2003-01-31 2013-11-04 Monsanto Technology Llc Glyphosattolerante lucerne-begivenheder og fremgangsmåder til detektering deraf
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US7846906B2 (en) 2003-02-28 2010-12-07 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
AU2004260737B2 (en) * 2003-07-10 2009-09-10 Intervet International B.V. Babesia vaccines
US7910563B2 (en) * 2003-08-12 2011-03-22 Antisense Pharma Gmbh Antisense oligonucleotide to inhibit melanoma inhibitory activity, MIA
US8227193B2 (en) * 2003-10-01 2012-07-24 The Regents Of The University Of California Compositions and methods for gene expression
ATE441728T1 (de) * 2003-10-27 2009-09-15 Fnp Corp Ltd Mit cmv-resistenz assoziierter molekularer marker und verwendung davon
EP1689889B1 (fr) * 2003-12-01 2017-08-30 Epigenomics AG Procedes et acides nucleiques pour l'analyse de l'expression genique associee a la survenue de troubles cellulaires proliferants de la prostate
JP2007520222A (ja) * 2004-01-20 2007-07-26 アイシス ファーマシューティカルズ インコーポレイテッド グルココルチコイドレセプター発現の調節
WO2005094219A2 (fr) * 2004-03-24 2005-10-13 United States Army Medical Research And Materiel Command Sequence chromosomique propre a bacillus anthracis et methodes de production et d'utilisation de la sequence, y compris des dosages pcr en temps reel
AU2005229157B2 (en) * 2004-03-31 2011-07-21 Commonwealth Scientific And Industrial Research Organisation Genes involved in plant fibre development
ES2547381T3 (es) 2004-04-09 2015-10-05 Monsanto Technology, Llc Composiciones y procedimientos de control de infestaciones de insectos en plantas
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
US20050287558A1 (en) * 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
ATE499614T1 (de) * 2004-05-24 2011-03-15 Anamar Ab Verfahren zur bestimmung eines gewebeabbauverfahrens durch nachweis von comp- neoepitopen
GB2414400B (en) 2004-05-28 2009-01-14 Cilag Ag Int Injection device
GB2414406B (en) 2004-05-28 2009-03-18 Cilag Ag Int Injection device
GB2414775B (en) 2004-05-28 2008-05-21 Cilag Ag Int Releasable coupling and injection device
GB2414403B (en) 2004-05-28 2009-01-07 Cilag Ag Int Injection device
GB2414399B (en) 2004-05-28 2008-12-31 Cilag Ag Int Injection device
GB2414401B (en) 2004-05-28 2009-06-17 Cilag Ag Int Injection device
GB2414402B (en) 2004-05-28 2009-04-22 Cilag Ag Int Injection device
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US20050287667A1 (en) * 2004-06-01 2005-12-29 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US7807647B2 (en) * 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
AU2005330267A1 (en) * 2004-07-28 2006-10-12 Canon U.S. Life Sciences, Inc. Methods for monitoring genomic DNA of organisms
EP2409713B1 (fr) * 2004-08-10 2015-07-22 Genzyme Corporation Oligonucléotides pour l'utilisation dans la modulation des niveaux de lipoprotéine et cholestérol chez l'homme
US7759479B1 (en) * 2004-09-13 2010-07-20 Isis Pharmaceuticals, Inc. Compositions and their uses directed to Gemin Genes
KR101138862B1 (ko) 2005-02-14 2012-05-14 삼성전자주식회사 단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법
JP4982387B2 (ja) * 2005-02-18 2012-07-25 キヤノン ユー．エス． ライフ サイエンシズ， インコーポレイテッド 微生物のゲノムｄｎａを同定するデバイスおよび方法
US20070185044A1 (en) * 2005-03-08 2007-08-09 Dobie Kenneth W Modulation of ace2 expression
GB2424836B (en) 2005-04-06 2010-09-22 Cilag Ag Int Injection device (bayonet cap removal)
GB2427826B (en) 2005-04-06 2010-08-25 Cilag Ag Int Injection device comprising a locking mechanism associated with integrally formed biasing means
GB2425062B (en) 2005-04-06 2010-07-21 Cilag Ag Int Injection device
DE602006014155D1 (de) * 2005-07-06 2010-06-17 Nestec Sa Dehydringene und promotoren aus kaffee
DE602005018480D1 (de) 2005-08-30 2010-02-04 Cilag Gmbh Int Nadelvorrichtung für eine vorgefüllte Spritze
AU2014277737B2 (en) * 2005-09-16 2017-02-02 Monsanto Technology Llc Methods for genetic control of insect infestations in plants and compositions thereof
RU2478710C2 (ru) 2005-09-16 2013-04-10 Монсанто Текнолоджи Ллс Способы генетического контроля поражения растений насекомыми и применяемые для этого композиции
US20110098656A1 (en) 2005-09-27 2011-04-28 Burnell Rosie L Auto-injection device with needle protecting cap having outer and inner sleeves
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
US8367628B2 (en) 2005-12-01 2013-02-05 Pronai Therapeutics, Inc. Amphoteric liposome formulation
EP2013345A2 (fr) * 2006-03-16 2009-01-14 Isis Pharmaceuticals, Inc. Compositions et procédés de modulation de l'expression de mcl-1
JP5825754B2 (ja) 2006-05-05 2015-12-02 アイシス ファーマシューティカルズ， インコーポレーテッド Ａｐｏｂの発現を調節するための化合物および方法
US8084734B2 (en) * 2006-05-26 2011-12-27 The George Washington University Laser desorption ionization and peptide sequencing on laser induced silicon microcolumn arrays
GB2438593B (en) 2006-06-01 2011-03-30 Cilag Gmbh Int Injection device (cap removal feature)
GB2438590B (en) 2006-06-01 2011-02-09 Cilag Gmbh Int Injection device
GB2438591B (en) 2006-06-01 2011-07-13 Cilag Gmbh Int Injection device
US7745595B2 (en) * 2006-08-10 2010-06-29 Medical Diagnostic Laboratories, Llc Compositions and methods for detecting Atopobium vaginae
AU2014200037B2 (en) * 2006-10-10 2016-06-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
US8188255B2 (en) 2006-10-20 2012-05-29 Exiqon A/S Human microRNAs associated with cancer
EP2090665A2 (fr) * 2006-10-20 2009-08-19 Exiqon A/S Nouveaux micro ARN humains associés au cancer
KR20090128494A (ko) 2007-03-24 2009-12-15 겐자임 코포레이션 인간 아포리포프로틴 ｂ에 상보적인 안티센스 올리고뉴클레오타이드 투여
JP2011502515A (ja) * 2007-11-09 2011-01-27 アイシス ファーマシューティカルズ インコーポレイティッド 第９因子発現の調節
ES2694284T3 (es) * 2007-11-23 2018-12-19 Epigenomics Ag Métodos y usos de los ácidos nucleicos para el análisis de la metilación y la expresión de genes, en particular de NFATC3, asociados con trastornos proliferativos de células de la próstata
CN102899415B (zh) * 2007-11-30 2014-12-10 基因特力株式会社 使用膀胱癌特异性甲基化标记基因的膀胱癌诊断试剂盒和芯片
EP2246422A4 (fr) * 2008-01-24 2012-07-25 Nat Inst Of Advanced Ind Scien Polynucléotide ou son analogue, et procédé de régulation de l'expression génétique utilisant le polynucléotide ou son analogue
US10150990B2 (en) * 2008-04-21 2018-12-11 Roche Molecular Systems, Inc. Ribonucleotide tag nucleic acid detection
GB2461086B (en) 2008-06-19 2012-12-05 Cilag Gmbh Int Injection device
GB2461084B (en) 2008-06-19 2012-09-26 Cilag Gmbh Int Fluid transfer assembly
GB2461089B (en) 2008-06-19 2012-09-19 Cilag Gmbh Int Injection device
GB2461085B (en) 2008-06-19 2012-08-29 Cilag Gmbh Int Injection device
GB2461087B (en) 2008-06-19 2012-09-26 Cilag Gmbh Int Injection device
US8110796B2 (en) 2009-01-17 2012-02-07 The George Washington University Nanophotonic production, modulation and switching of ions by silicon microcolumn arrays
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
CN102439149B (zh) * 2009-02-12 2018-01-02 库尔纳公司 通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
ES2762610T3 (es) * 2009-02-12 2020-05-25 Curna Inc Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
US9107933B2 (en) 2009-03-16 2015-08-18 Isis Pharmaceuticals, Inc. Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
US9490113B2 (en) * 2009-04-07 2016-11-08 The George Washington University Tailored nanopost arrays (NAPA) for laser desorption ionization in mass spectrometry
CN102762731B (zh) * 2009-08-05 2018-06-22 库尔纳公司 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
EP2322656A1 (fr) * 2009-11-17 2011-05-18 Centre National de la Recherche Scientifique (C.N.R.S) Procédés de diagnostic de maladies de la peau
GB201008719D0 (en) * 2010-05-25 2010-07-07 Nat Univ Ireland Diagnostic method
EP2575818A4 (fr) 2010-06-03 2013-11-06 Pharmacyclics Inc Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
DK2585596T3 (da) * 2010-06-23 2021-04-06 Curna Inc Behandling af spændingsreguleret natriumkanal-alpha-underenhed (scna)-relaterede sygdomme ved inhibering af naturligt antisense-transkript til scna
WO2012012443A2 (fr) 2010-07-19 2012-01-26 Bennett C Frank Modulation de l'expression de la protéine kinase de la dystrophie myotonique (dmpk)
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
CN103210087B (zh) * 2010-09-06 2015-04-29 淡马锡生命科学研究院有限公司 Xa10与AvrXa10之间的分子相互作用
WO2012038827A2 (fr) * 2010-09-20 2012-03-29 Prognomix Inc. Gènes communs à plusieurs complications du diabète de type 2 (t2d)
US8648053B2 (en) * 2010-10-20 2014-02-11 Rosalind Franklin University Of Medicine And Science Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
AU2011329777B2 (en) * 2010-11-17 2016-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
AU2013206424B2 (en) * 2010-11-24 2015-09-17 E. I. Du Pont De Nemours And Company Brassica gat event dp-073496-4 and compositions and methods for the identification and/or detection thereof
US9085808B2 (en) * 2011-01-12 2015-07-21 Abbott Molecular Inc. Materials and method for detecting cytomegalovirus (CMV)
US9157125B2 (en) 2011-02-02 2015-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services GRIN2A mutations and use thereof for the diagnosis of melanoma
MY185926A (en) * 2011-07-15 2021-06-14 Acgt Sdn Bhd Ssr markers for plants and uses thereof
JP6085603B2 (ja) * 2011-08-25 2017-02-22 クリニカル ゲノミクス プロプライエタリー リミテッド 結腸直腸がん及び乳がん診断法におけるｄｎａメチル化
JP6092226B2 (ja) * 2011-09-20 2017-03-08 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｇｃｇｒ発現のアンチセンス調整
HUE039835T2 (hu) 2011-10-17 2019-02-28 Novozymes As Alfa-amiláz variánsok és az azokat kódoló polinukleotidok
US9567585B2 (en) 2011-11-10 2017-02-14 Shire Human Genetic Therapies, Inc. Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof
US20150031015A1 (en) * 2011-12-14 2015-01-29 De Staat der Nederlanden, Vert. Door De Minister Van VWS, Ministerie van Volksgezondheid, Welzijn Identification of poliovirus strains
EP2831232A4 (fr) 2012-03-30 2015-11-04 Univ Washington Procédés de modulation de l'expression de tau pour réduire l'avc et modifier un symptôme neurodégénératif
KR20160074368A (ko) 2012-05-16 2016-06-28 라나 테라퓨틱스, 인크. Utrn 발현을 조절하기 위한 조성물 및 방법
WO2013173598A1 (fr) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions et méthodes pour moduler l'expression de atp2a2
JP2015518710A (ja) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法
DK2850186T3 (en) 2012-05-16 2019-04-08 Translate Bio Ma Inc COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2013173608A1 (fr) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions et méthodes pour moduler l'expression de mecp2
WO2014018375A1 (fr) * 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 et ses utilisations dans des méthodes thérapeutiques et diagnostiques
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
WO2014034952A1 (fr) * 2012-09-03 2014-03-06 国立大学法人九州大学 Procédé pour prévoir l'efficacité d'une immunothérapie contre le cancer
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
CN105247051A (zh) * 2013-02-28 2016-01-13 箭头研究公司 治疗epas1相关疾病的有机组合物
US9359643B2 (en) 2013-03-08 2016-06-07 Progenika Biopharma S.A. Discrimination of blood type variants
BR112015022156A2 (pt) * 2013-03-14 2017-11-14 Isis Pharmaceuticals Inc composições e métodos para modular a expressão de tau
EP2971103A1 (fr) * 2013-03-14 2016-01-20 Cepheid Méthodes de détection du cancer du poumon
CN110041427B (zh) * 2013-03-15 2023-05-23 本质生命科学有限公司 抗铁调素抗体及其用途
GB2517896B (en) 2013-06-11 2015-07-08 Cilag Gmbh Int Injection device
GB2515039B (en) 2013-06-11 2015-05-27 Cilag Gmbh Int Injection Device
GB2515038A (en) 2013-06-11 2014-12-17 Cilag Gmbh Int Injection device
GB2515032A (en) 2013-06-11 2014-12-17 Cilag Gmbh Int Guide for an injection device
WO2015188899A1 (fr) * 2014-06-12 2015-12-17 Deutsches Krebsforschungszentrum Nouvelles séquences de micro-arn du virus torque teno, ttv, utiles en tant que marqueur précoce du développement futur de cancers et en tant que cible pour le traitement et la prévention du cancer
JP6487913B2 (ja) * 2013-07-02 2019-03-20 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 成長ホルモン受容体のモジュレータ
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
TW201536329A (zh) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
GB201315527D0 (en) * 2013-08-30 2013-10-16 Sec Dep For Health The Assay for the detection of infection-causing e.coli strains
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
CA2924277A1 (fr) * 2013-10-18 2015-04-23 Institut De Cardiologie De Montreal Tests de genotypage et procedes d'evaluation des taux de creatine kinase dans le plasma
US20160186261A1 (en) * 2013-11-04 2016-06-30 Jose U. Scher Prevotella copri and enhanced susceptibility to arthritis
WO2015143400A1 (fr) * 2014-03-20 2015-09-24 Pharmacyclics, Inc. Mutations de phospholipase c gamma 2 et associées aux résistances
MX2016012922A (es) 2014-04-01 2017-01-26 Ionis Pharmaceuticals Inc Composiciones para modular la expresion de sod-1.
CN106459969B (zh) 2014-05-01 2019-11-15 Ionis制药公司 用于调节生长激素受体表达的组合物和方法
TWI703214B (zh) * 2014-07-31 2020-09-01 中央研究院 具拮抗ｐｄ-１功能的適體分子於癌症治療相關之應用
US10731163B2 (en) * 2014-09-02 2020-08-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Oligonucleotide targeted to the A20-3′ untranslated region
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US20170356052A1 (en) * 2014-11-18 2017-12-14 Blueprint Medicines Corporation Prkacb fusions
US10604769B2 (en) * 2015-11-02 2020-03-31 Monsanto Technology Llc Cotton transgenic event MON 88702 and methods for detection and uses thereof
AU2017221405A1 (en) 2016-02-16 2018-09-20 Carnegie Mellon University Compositions for enhancing targeted gene editing and methods of use thereof
AU2017277666B2 (en) * 2016-06-08 2023-07-27 University Of Iowa Research Foundation Compositions and methods for detecting predisposition to cardiovascular disease
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
AU2017339561B2 (en) 2016-10-07 2024-02-01 Secarna Pharmaceuticals Gmbh & Co. Kg Novel approach for treating cancer
NO344051B1 (en) * 2017-05-04 2019-08-26 Patogen As Novel virus in Fish and Method for detection
US11814626B2 (en) 2017-05-11 2023-11-14 The Research Foundation For The State University Of New York Compositions and methods for loading extracellular vesicles with chemical and biological agents/molecules
GB201708617D0 (en) * 2017-05-31 2017-07-12 Blue Genomics Chile Spa Salmonid genetics
GB201711782D0 (en) * 2017-07-21 2017-09-06 Ucl Business Plc Diagnostic and Prognostic methods
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
AU2019208006A1 (en) 2018-01-12 2020-07-23 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
TW202000199A (zh) 2018-03-02 2020-01-01 美商Ionis製藥公司 Irf4 表現之調節劑
CA3094020A1 (fr) 2018-04-11 2019-10-17 Ionis Pharmaceuticals, Inc. Modulateurs de l'expression de l'ezh2
AU2019255192B2 (en) * 2018-04-18 2023-02-02 Pioneer Hi-Bred International, Inc. Genes, constructs and maize event DP-202216-6
BR112020017892A2 (pt) * 2018-05-18 2020-12-22 Olipass Corporation Derivado de ácido nucleico peptídico, método para tratamento de doenças ou condições associadas à transcrição do gene da mmp-1 humana, método para tratamento do envelhecimento da pele, composição farmacêutica e composição cosmética
JP7379387B2 (ja) 2018-06-05 2023-11-14 エフ． ホフマン－ラ ロシュ アーゲー Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
EP3693465A1 (fr) * 2019-02-05 2020-08-12 Pharmaq AS Nouveau coronavirus du poisson
WO2020172559A1 (fr) * 2019-02-22 2020-08-27 Ionis Pharmaceuticals, Inc. Composés et méthodes pour réduire l'expression d'atxn3
US11286485B2 (en) 2019-04-04 2022-03-29 Hoffmann-La Roche Inc. Oligonucleotides for modulating ATXN2 expression
CN110343764B (zh) * 2019-07-22 2020-05-26 武汉艾米森生命科技有限公司 检测结直肠癌相关基因甲基化的检测试剂的应用和试剂盒
JP7386507B2 (ja) 2019-08-02 2023-11-27 国立大学法人信州大学 筋分化促進剤および筋分化促進方法および筋分化促進オリゴｄｎａ
WO2021154674A1 (fr) * 2020-01-27 2021-08-05 Pioneer Hi-Bred International, Inc. Événement de maïs mon87429 et ses procédés d'utilisation
CN115103919A (zh) * 2020-02-17 2022-09-23 3M创新有限公司 用于副溶血弧菌检测的环介导的等温扩增引物及其用途
DE102020108560B4 (de) * 2020-03-27 2022-03-03 Precision For Medicine Gmbh CBX6 als epigenetischer Marker für die Identifizierung von Immunzellen, insbesondere Gedächtnis-B-Zellen
JP2023534720A (ja) * 2020-07-22 2023-08-10 ザ フローリー インスティテュート オブ ニューロサイエンス アンド メンタル ヘルス Ｓｃｎ２ａ中の機能喪失変異に関連する障害を処置するための組成物及び方法
AU2022316149A1 (en) * 2021-07-21 2024-02-08 AcuraStem Incorporated Unc13a antisense oligonucleotides
US11833221B2 (en) 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
EP0730663B1 (fr) * 1993-10-26 2003-09-24 Affymetrix, Inc. Reseaux de sondes d'acide nucleique sur des microplaquettes biologiques
DE19754482A1 (de) * 1997-11-27 1999-07-01 Epigenomics Gmbh Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO0177384A3 *

Also Published As

Publication number Publication date
WO2001077384A3 (fr) 2002-07-25
AU2001250572A1 (en) 2001-10-23
WO2001077384A2 (fr) 2001-10-18
US20040241651A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2001077384A2 (fr) Detection de polymorphismes du nucleotide simple et de methylation de cytosine
EP1423528B1 (fr) Procede de determination du degre de methylation de cytosines determinees d'adn genomique dans le contexte sequentiel 5'-cpg-3'
DE10010280B4 (de) Verfahren zur Detektion von Cytosin-Methylierung in DNA Proben
DE10056802B4 (de) Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik
DE10151055B4 (de) Verfahren zum Nachweis von Cytosin-Methylierung in CpG Inseln
WO2002018631A2 (fr) Diagnostic de maladies declarees ou de la predisposition a certaines maladies
DE10154317B4 (de) Verfahren zum Nachweis von Cytosin-Methylierungen in immobilisierten DNA Proben
DE10132212B4 (de) Verfahren zum Nachweis von Cytosin-Methylierung durch vergleichende Analyse der Einzelstränge von Amplifikaten
DE10010282B4 (de) Verfahren zur Detektion von Cytosin-Methylierung in DNA Proben
WO2002083943A2 (fr) Procede a microreseau permettant d'enrichir des fragments d'adn provenant de melanges complexes
EP1292711B1 (fr) Procede pour l'analyse ultraparallele de polymorphismes
DE10128508A1 (de) Verfahren und Nukleinsäuren für die Differenzierung von Prostata-Tumoren
WO2002036814A2 (fr) Diagnostic de maladies associees au gene cdk4
EP1320632B1 (fr) Procede servant a determiner l'age d'individus
EP1339873B1 (fr) Diagnostic de maladies associees au gene c-mos humain
DE10013847A1 (de) Oligonukleotide oder PNA-Oligomere und Verfahren zur parallelen Detektion des Methylierungszustandes genomischer DNA
WO2004022779A2 (fr) Procede de detection de sequences d'acides nucleiques au moyen de molecules sonde comportant une liaison cassable
DE10044543C2 (de) Verfahren zur Bestimmung des Methylierungsgrades von bestimmten Cytosinen in genomischer DNA im Sequenzkontext 5'-CpG-3'
EP1451359A2 (fr) Procede et dispositif integre permettant de deceler des methylations de la cytosine
DE20121967U1 (de) Nukleinsäuren für die Diagnose von Verhaltensstörungen, neurologischen Erkrankungen und Krebs
DE20121965U1 (de) Nukleinsäuren für die Diagnose von mit DNA Addukten assoziierten Krankheiten
DE20121974U1 (de) Nukleinsäuren für die Diagnose von mit DNA Replikation assoziierten Krankheiten
DE20121964U1 (de) Nukleinsäuren für die Diagnose von mit dem Metabolismus assoziierten Krankheiten
DE20121979U1 (de) Nukleinsäuren für die Diagnose von mit der Zellsignalisierung assoziierten Krankheiten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021009

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL PAYMENT 20021009;LT PAYMENT 20021009;LV PAYMENT 20021009;MK PAYMENT 20021009;RO PAYMENT 20021009;SI PAYMENT 20021009

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EPIGENOMICS AG

17Q First examination report despatched

Effective date: 20070212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070623